Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation

被引：2

作者：

Jin, Xin ^{[1
,2
]}

Ma, Xiaoting ^{[3
]}

Zhao, Dong ^{[1
,2
]}

Yang, Lin ^{[3
]}

Ma, Nan ^{[1
,2
]}

机构：

[1] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Div Liver Surg, Natl Clin Res Ctr Infect Dis,Affiliated Hosp 2, 29 Bulan Rd, Shenzhen 518112, Guangdong, Peoples R China

[2] Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Organ Transplantat Ctr, Natl Clin Res Ctr Infect Dis,Affiliated Hosp 2, 29 Bulan Rd, Shenzhen 518112, Guangdong, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Med Oncol,Canc Hosp, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China

来源：

TRANSLATIONAL ONCOLOGY | 2023年 / 28卷

关键词：

ICI; HCC; Liver transplantation; PD-1; Tumor recurrence; T-CELLS; CHECKPOINT INHIBITORS; PD-1; IMMUNOSUPPRESSION; TACROLIMUS; TOLERANCE; PATHWAY;

D O I：

10.1016/j.tranon.2022.101603

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

HCC is a highly lethal tumor, and orthotopic liver transplantation, as one of the radical treatment methods for HCC, has opened-up a new therapeutic approach for the treatment of primary liver cancer. However, tumor recurrence after liver transplantation is the main reason that affects the long-term survival of recipients. At present, the application of ICIs has brought dawn to patients with refractory HCC. However, because of the special immune tolerance state created by long-term oral immunosuppressants in patients with HCC after liver transplantation, the current focus is how to regulate the immune balance of such patients and simultaneously maximize the anti-tumor effect. This article reviews the relationship between liver cancer and immunity, im-mune tolerance of liver transplantation, immune microenvironment after liver transplantation for HCC, and the application of immunotherapy in the recurrence of liver transplantation for HCC.

引用

页数：7

共 55 条

[1] Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature [J].